Sientra Announces FDA-Clearance Of Next Generation AlloX2 Pro Tissue Expander
Portfolio Pulse from Benzinga Newsdesk
Sientra has announced FDA clearance for its next-generation AlloX2 Pro Tissue Expander, a device used in breast reconstruction procedures. This approval is expected to strengthen Sientra's product portfolio.
June 08, 2023 | 8:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sientra's FDA clearance for the AlloX2 Pro Tissue Expander is expected to enhance its product portfolio and potentially boost revenues.
The FDA clearance of Sientra's AlloX2 Pro Tissue Expander directly impacts the company as it expands their product portfolio. This approval can lead to increased adoption of the product by healthcare providers, potentially resulting in higher revenues for Sientra. As a result, the stock price is likely to go up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100